Corrigendum: Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR

Corrigendum: Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR

Bibliographic Details
Main Authors:	Jun-ming Huang, Ran-yue Ren, Yuan Bao, Jia-chao Guo, Wei Xiang, Xing-zhi Jing, Jia Shi, Guo-xiang Zhang, Long Li, Yong Tian, Hao Kang, Feng-jin Guo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-10-01
Series:	Frontiers in Pharmacology
Subjects:	ulinastatin uPAR osteoclast MAPKs NF-kB RANKL
Online Access:	https://www.frontiersin.org/article/10.3389/fphar.2018.01128/full

Similar Items

Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR
by: Jun-ming Huang, et al.
Published: (2018-09-01)

Corrigendum: Meclizine Prevents Ovariectomy-Induced Bone Loss and Inhibits Osteoclastogenesis Partially by Upregulating PXR
by: Jiachao Guo, et al.
Published: (2018-01-01)

Meclizine Prevents Ovariectomy-Induced Bone Loss and Inhibits Osteoclastogenesis Partially by Upregulating PXR
by: Jiachao Guo, et al.
Published: (2017-10-01)

Schisandrin B Inhibits Osteoclastogenesis and Protects Against Ovariectomy-Induced Bone Loss
by: Jia Wang, et al.
Published: (2020-07-01)

Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin
by: Oh F, et al.
Published: (2018-09-01)

Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion
by: Matthew G. Annis, et al.
Published: (2018-01-01)

Identification of uPAR Variants Acting as ceRNAs in Leukaemia Cells
by: Alfieri, M., et al.
Published: (2022)

Targeting uPAR by CRISPR/Cas9 System Attenuates Cancer Malignancy and Multidrug Resistance
by: Kun Wang, et al.
Published: (2019-02-01)

Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor
by: Gujrati Meena, et al.
Published: (2011-10-01)

Carbon Monoxide Inhibits Receptor Activator of NF-κB (RANKL)-Induced Osteoclastogenesis
by: Feng-Jen Tseng, et al.
Published: (2015-07-01)

Corrigendum: A Matrine Derivative M54 Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Targeting Ribosomal Protein S5
by: Zhi Xin, et al.
Published: (2021-03-01)

New Pieces in the Puzzle of uPAR Role in Cell Migration Mechanisms
by: Anna Gorrasi, et al.
Published: (2020-11-01)

Inhibiting Monoacylglycerol Lipase Suppresses RANKL-Induced Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss
by: Hui Liu, et al.
Published: (2021-03-01)

Inhibitory effects of ChondroT and its constituent herbs on RANKL-induced osteoclastogenesis
by: Rui Hong Guo, et al.
Published: (2019-11-01)

uPAR und c-MYC beim duktalen Adenokarzinom des Pankreas
by: Fuchs, Frieder
Published: (2018)

Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention
by: Julie Maja Leth, et al.
Published: (2021-08-01)

Vindoline Inhibits RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss in Mice
by: Yunfei Zhan, et al.
Published: (2020-01-01)

A Matrine Derivative M54 Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Targeting Ribosomal Protein S5
by: Zhi Xin, et al.
Published: (2018-01-01)

Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer
by: Anders Christensen, et al.
Published: (2017-08-01)

Determining Biological Effectors of alpha6 Integrin Cleavage
by: Kacsinta, Apollo Daniel
Published: (2010)

The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications
by: Anna Li Santi, et al.
Published: (2021-04-01)

Inflammatory osteolysis is regulated by site-specific ISGylation of the scaffold protein NEMO
by: Naga Suresh Adapala, et al.
Published: (2020-03-01)

Growth Inhibition of MDA-MB-231 Cell Line by Peptides Designed based on uPA
by: Parastoo Tarighi, et al.
Published: (2015-10-01)

Guizhi-Shaoyao-Zhimu decoction attenuates bone erosion in rats that have collagen-induced arthritis via modulating NF‐κB signalling to suppress osteoclastogenesis
by: Shu-jun Wei, et al.
Published: (2021-01-01)

suPAR, a Circulating Kidney Disease Factor
by: Changli Wei, et al.
Published: (2021-10-01)

<i>Helicobacter pylori</i> Colonization Drives Urokinase Receptor (uPAR) Expression in Murine Gastric Epithelium During Early Pathogenesis
by: Warner Alpízar-Alpízar, et al.
Published: (2020-07-01)

Evaluation of the Pharmacological Function of Ulinastatin in Experimental Animals
by: Ling Guo, et al.
Published: (2012-07-01)

CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy
by: Daan Linders, et al.
Published: (2021-03-01)

Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography
by: Baoyu Zhao, et al.
Published: (2015-12-01)

The Role of the Plasminogen Activation System in Angioedema: Novel Insights on the Pathogenesis
by: Filomena Napolitano, et al.
Published: (2021-02-01)

Effect of ulinastatin on the rocuronium-induced neuromuscular blockade
by: Min Soo Kim, et al.
Published: (2012-03-01)

Egg White Ovotransferrin Attenuates RANKL-Induced Osteoclastogenesis and Bone Resorption
by: Nan Shang, et al.
Published: (2019-09-01)

Protective effect of ulinastatin on acute lung injury after radiotherapy in patients with lung cancer and the related molecular mechanism
by: Guang-Ping Fan
Published: (2016-12-01)

uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study
by: Marie Øbro Fosbøl, et al.
Published: (2021-06-01)

Fibrinolytic System and Cancer: Diagnostic and Therapeutic Applications
by: Niaz Mahmood, et al.
Published: (2021-04-01)

Protective Effects of Fermented Oyster Extract against RANKL-Induced Osteoclastogenesis through Scavenging ROS Generation in RAW 264.7 Cells
by: Jin-Woo Jeong, et al.
Published: (2019-03-01)

Niclosamide and its derivative DK‐520 inhibit RANKL‐induced osteoclastogenesis
by: Yurui Jiao, et al.
Published: (2020-08-01)

Clathrin-dependent endocytosis of membrane-bound RANKL in differentiated osteoclasts
by: P. Narducci, et al.
Published: (2010-03-01)

NRF2 is an Upstream Regulator of MYC-Mediated Osteoclastogenesis and Pathological Bone Erosion
by: Peter Sang Uk Park, et al.
Published: (2020-09-01)

Effect of ulinastatin combined with atomolam therapy on myocardial inflammatory injury and oxidative damage in patients with septic shock
by: Xiang-Ming Fang, et al.
Published: (2016-12-01)